Perf-A-Tape Cement

Product Description

Perf-A-Tape Cement was a specialty joint compound manufactured by United States Gypsum Company (USG), one of the dominant producers of wallboard and finishing materials in North America throughout the twentieth century. Produced from approximately 1944 through 1976, the product was designed for use in drywall finishing applications, functioning as an embedding and finishing compound intended to be used in conjunction with perforated paper joint tape. The cement was formulated to adhere tape over wallboard seams and corners, creating smooth, continuous wall surfaces ready for painting or further finishing.

USG held a commanding position in the gypsum and drywall products market during the postwar construction boom, and Perf-A-Tape Cement was among the company’s product lines marketed to contractors, builders, and industrial facilities engaged in large-scale construction and renovation. The compound was available in both dry powder and pre-mixed forms depending on the application period, and it was used across a range of industrial and commercial building environments throughout its years of production. The product line was discontinued prior to or concurrent with increased regulatory scrutiny of asbestos-containing building materials in the mid-1970s, following the Environmental Protection Agency’s growing body of guidance on asbestos hazards and OSHA’s initial asbestos standards enacted in 1971.

Asbestos Content

Perf-A-Tape Cement contained chrysotile asbestos as a functional ingredient in its formulation. Chrysotile, also known as white asbestos, is the most commercially prevalent form of asbestos and belongs to the serpentine mineral group. It was incorporated into joint compounds and finishing cements by manufacturers during this era because of its practical material properties: chrysotile fibers improved workability, aided in binding and adhesion, reduced cracking during drying and curing, and contributed to the overall structural integrity of the finished joint.

USG’s use of asbestos in joint compounds, including products like Perf-A-Tape Cement, was consistent with widespread industry practice during the mid-twentieth century. Chrysotile fibers were readily available, inexpensive, and considered a reliable additive for improving performance characteristics in gypsum-based compounds. The mineral was sourced through established commercial supply chains throughout the product’s production run from 1944 to 1976.

Under the Asbestos Hazard Emergency Response Act (AHERA) and subsequent regulatory frameworks, chrysotile asbestos is classified as a known human carcinogen. All commercial forms of asbestos, including chrysotile, are associated with mesothelioma, asbestosis, lung cancer, and other serious pulmonary diseases following sufficient inhalation exposure to airborne fibers.

How Workers Were Exposed

Workers identified in the context of Perf-A-Tape Cement exposure are documented broadly as industrial workers, reflecting the range of construction and industrial facility environments in which the product was applied. Exposure to asbestos from joint compounds like Perf-A-Tape Cement occurred primarily through the generation of airborne chrysotile fibers during the handling, mixing, application, sanding, and finishing of the compound.

Dry powder joint compounds of this type presented particular inhalation hazards during the mixing stage, when workers would add water to the powder in enclosed or semi-enclosed spaces, releasing respirable asbestos fibers into the breathing zone. Pre-mixed formulations similarly released fibers during application and, critically, during the sanding and feathering of dried compound, which is recognized as one of the most fiber-intensive tasks associated with drywall finishing work.

Industrial worksites—including manufacturing plants, warehouses, shipyards, power generation facilities, and other large commercial structures built or renovated during the postwar period—frequently employed drywall and finishing systems that incorporated asbestos-containing joint compounds. Workers in these environments who mixed, applied, or sanded Perf-A-Tape Cement or who worked in proximity to those performing such tasks could have inhaled chrysotile fibers over sustained periods. Bystander exposure was also a recognized mechanism, as airborne asbestos fibers disturbed during finishing work do not settle immediately and can remain suspended in worksite air for extended periods.

OSHA’s asbestos standards, first promulgated in 1971 and subsequently revised and strengthened, established permissible exposure limits (PELs) for asbestos in occupational settings. The regulatory record surrounding these standards acknowledges that prior to formal rulemaking, workers in trades involving asbestos-containing materials frequently labored without adequate engineering controls, respiratory protection, or hazard communication.

Perf-A-Tape Cement is a Tier 2 product for purposes of legal classification, meaning that claims associated with this product have proceeded through civil litigation rather than through an established asbestos bankruptcy trust fund. No USG asbestos trust fund exists that corresponds to claims arising from Perf-A-Tape Cement specifically under the terms applicable to this product.

Litigation records document that plaintiffs have alleged personal injury arising from exposure to asbestos-containing products manufactured by United States Gypsum Company, including joint compounds used in industrial and commercial construction settings. Plaintiffs alleged that USG knew or had reason to know of the hazards associated with asbestos inhalation during the product’s period of manufacture, and that the company failed to adequately warn workers of those hazards or to reformulate its products to eliminate the asbestos content in a timely manner.

Litigation records further document claims in which plaintiffs alleged that exposure to chrysotile-containing USG products, including finishing cements used in the drywall trade and in industrial facility construction, was a substantial contributing factor in the development of mesothelioma, lung cancer, and asbestosis. These claims have been brought in various state and federal jurisdictions by workers and, where applicable, their surviving family members.

Individuals who worked in industrial environments where Perf-A-Tape Cement was mixed, applied, or sanded, or who worked in proximity to such activities during the product’s production years of 1944 through 1976, may have legal options available to them. Because no dedicated trust fund exists for this product, potential remedies lie in direct litigation against United States Gypsum or its successor entities, as well as potential claims against other parties in the chain of supply or other manufacturers whose products may have contributed to cumulative asbestos exposure in the same work environments.

Those with a diagnosis of mesothelioma, asbestosis, or asbestos-related lung cancer and a documented history of work in environments where Perf-A-Tape Cement or similar USG joint compounds were in use are encouraged to consult with an attorney experienced in asbestos litigation. Statutes of limitations governing asbestos personal injury and wrongful death claims vary by state and generally begin to run from the date of diagnosis or the date on which a claimant reasonably should have known of the connection between their illness and asbestos exposure.